DA01 IND Cleared for Parkinson’s Disease

In early January 2021, biopharmaceutical company BlueRock Therapeutics ("BlueRock"), in collaboration with the Memorial Sloan Kettering Cancer Center, announced via press release that its Investigational New Drug (IND) application for…

Continue Reading DA01 IND Cleared for Parkinson’s Disease